Last edition
News about "pharmacokinetics "
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Pharmacokinetics | 11/11/2025 | By Dineshwori | 150
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Pharmacokinetics | 13/10/2025 | By Dineshwori | 187
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
Pharmacokinetics | 11/10/2025 | By Dineshwori | 361
Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101
The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.
Pharmacokinetics | 15/09/2025 | By Dineshwori
TUL Signs Exclusive License Deal with Novo Nordisk for UBT251
Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.
Pharmacokinetics | 25/03/2025 | By Aishwarya | 280
Adcendo Receives FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
Tiffany-01 is an ongoing first-in-human Phase I multicenter, open-label, dose escalation study of ADCE-T02 as a monotherapy in patients with advanced solid tumors.
Pharmacokinetics | 27/02/2025 | By Aishwarya | 472
Epigenic Therapeutics to Initiate Clinical Development of EPI-003
This first-in-human study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EPI-003 in Nucleos(t)ide Analogue-Treated, Chronic Hepatitis B Patients.
Pharmacokinetics | 20/11/2024 | By Aishwarya | 450
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy